Lui et al. performed high-throughput RNAi screening in different patient-derived ovarian cancer cells and found that knockdown of Bromodomain-containing protein 4 (BRD4) and other components of the transcriptional machinery sensitized cells to rucaparib (246). This evidence concerns the gene BRD4 and ovarian carcinoma.